AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



(I)

wherein

X represents O or S;

R^1 represents hydrogen, halogen, hydroxy, nitro, cyano, C_{1-6} alkoxy carbonyl, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkanoyl, phenyl, C_{1-6} alkyl optionally substituted by mono-, di- or tri- halogen, or C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen;

R^2 represents hydrogen, halogen, hydroxy, nitro, cyano, C_{1-6} alkoxy carbonyl, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkanoyl, phenyl, C_{1-6} alkyl optionally substituted by mono-, di- or tri- halogen, or C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen;

R^3 represents hydrogen, halogen, hydroxy, nitro, cyano, amino, carboxy, tetrazolyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{1-6} alkanoyl, C_{1-6} alkanoylamino, C_{1-6} alkyl optionally substituted by mono-, di- or tri- halogen or hydroxy;

R^4 represents



,



wherein:

R^{71} represents hydrogen, or C_{1-6} alkyl optionally substituted by amino, hydroxy, carboxy, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6} alkyl) amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di-oxo; and

Z^1 represents $-[CH_2]_p-$, wherein p represents an integer 1 or 2;

~~R^{81} represents hydrogen, C_{1-6} alkoxycarbonyl, or C_{1-6} alkyl substituted by pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;~~

~~R^{82} represents hydrogen, hydroxy, carboxy or C_{1-6} alkyl substituted by hydroxy, amino, or carboxy,~~

~~R^{83} represents hydrogen, hydroxy, carboxy or C_{1-6} alkyl substituted by hydroxy, amino, or carboxy,~~

~~with the proviso that when R^{81} is hydrogen, R^{82} or R^{83} is other than hydrogen;~~

~~Z^2 represents $-[CH_2]_q-$, wherein q represents an integer selected from 0 to 3;~~

~~A ring represents a 3 to 8 membered saturated heterocyclic ring, in which the nitrogen atom N^A is the only hetero atom; and~~

~~B ring represents a 3 to 8 membered saturated heterocyclic ring, in which the nitrogen atom N^B is the only hetero atom~~.

2. (Currently Amended) The compound of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein R^4 represents



,



,



,

~~or~~

wherein:

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6}alkyl)amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

~~R^{81} represents hydrogen, methoxycarbonyl or C_{1-6} alkyl substituted by 2-oxo-pyrrolidin-1-yl, 2,5-dioxo-pyrrolidin-1-yl 2-oxo-piperidin-1-yl, 2-oxo-piperidin-3-yl, 4-oxo-piperidin-1-yl, 2-oxo-piperidin-6-yl, 2,5-dioxo-~~

~~piperidin-1-yl, 2,6-dioxo-piperidin-1-yl, or 2,6-dioxo-piperidin-3-yl;~~

~~R^{82} represents hydrogen, hydroxy or hydroxy substituted C_{1-6}-alkyl; and~~

~~R^{83} represents hydrogen, hydroxy or carboxy;~~

~~with the proviso that when R^{82} and R^{83} are hydrogen at the same time, R^{81} is other than hydrogen, or when R^{81} and R^{83} are hydrogen at the same time, R^{82} is other than hydrogen~~.

3. (Currently Amended) The compound of claim 1, wherein the derivative is of the formula (I-b), its tautomeric or stereoisomeric form, or a salt thereof:



(I-b)

wherein:

R^1 represents fluoro, chloro, bromo, iodo, or nitro;

R^2 represents fluoro, chloro, bromo, iodo, or nitro;

R^3 represents acetyl, cyano, or tetrazolyl;

R^4 represents





wherein:

R^{71} represents hydrogen, or C_{1-6} alkyl optionally substituted by amino, hydroxy, carboxy, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6}alkyl)amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo; and

Z^1 represents $-[CH_2]_p-$, wherein p represents an integer 1 or 2;

~~R^{81} represents hydrogen, C_{1-6} alkoxycarbonyl, or C_{1-6} alkyl substituted by pyrrolidinyl, or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;~~

~~R^{82} represents hydrogen, hydroxy, carboxy or C_{1-6} alkyl substituted by hydroxy, amino, or carboxy,~~

~~R^{83} represents hydrogen, hydroxy, carboxy or C_{1-6} alkyl substituted by hydroxy, amino, or carboxy,~~

~~with the proviso that when R^{81} is hydrogen, R^{82} or R^{83} is other than hydrogen;~~

~~Z^2 represents $-[CH_2]_q-$,~~

~~wherein~~

~~q represents an integer selected from 0 to 3;~~

~~A ring represents a 3 to 8 membered saturated heterocyclic ring, in which the nitrogen atom N^A is the only hetero atom; and~~

~~B ring represents a 3 to 8 membered saturated heterocyclic ring, in which the nitrogen atom N^B is the only hetero atom~~.

4. (Currently Amended) The compound of claim 3, its tautomeric or stereoisomeric form, or a salt

wherein:

R^1 represents fluoro, chloro or bromo;

R^2 represents fluoro, chloro or bromo;

R^3 represents cyano;

R^4 represents











~~or~~

wherein:

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6}alkyl)amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo~~;~~

~~R^{81} represents hydrogen, methoxycarbonyl or C_{1-6} alkyl substituted by 2-oxo-pyrrolidin-1-yl, 2,5- dioxo_pyrrolidin-1-yl, or 2-oxo-piperidin-1-yl, 2-oxo-piperidin-3-yl, 4-oxo-piperidin-1-yl, 2-oxo-piperidin-6-yl, 2,5-dioxo-piperidin-1-yl, 2,6-dioxo-piperidin-1-yl, or 2,6-dioxo-piperidin-3-yl;~~

~~R^{82} represents hydrogen, hydroxy or hydroxy substituted C_{1-6} alkyl; and~~

~~R^{83} represents hydrogen, hydroxy or carboxy;~~

~~with the proviso that when R^{82} and R^{83} are hydrogen at the same time, R^{81} is other than hydrogen, or when R^{81} and R^{83} are hydrogen at the same time, R^{82} is other than hydrogen~~.

5. (Currently Amended) A compound of claim 1, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof, wherein said compound is selected from the group consisting of:

~~4-(3,5-Dichloro-phenoxy)-3-[(3R)-(2-hydroxy-ethylamino)-pyrrolidine-1-sulfonyl]-benzonitrile;~~

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-5-cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonamide;

(S)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-5-cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonamide;

~~4-(3,5-Dichloro-phenoxy)-3-{4-[(2S)-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-piperidine-1-sulfonyl}-benzonitrile;~~

~~5-Cyano-2-(3,5-dichloro-phenoxy)-N-(2-dimethylamino-ethyl)-N-[2-(2,5-dioxo-pyrrolidin-1-yl)-ethyl]-benzenesulfonamide;~~

~~4-(3,5-Dichloro-phenoxy)-3-[3-(2,5-dioxo-pyrrolidin-1-ylmethyl)-4-pyrrolidin-1-yl-piperidine-1-sulfonyl]-benzonitrile;~~

~~4-(3,5-Dichloro-phenoxy)-3-{4-[(2S)-hydroxymethyl-pyrrolidin-1-yl]-piperidine-1-sulfonyl}-benzonitrile;~~

~~4-(3,5-Dichloro-phenoxy)-3-{(2S)-[(2S)-hydroxymethyl-pyrrolidin-1-ylmethyl]-pyrrolidine-1-sulfonyl}-benzonitrile;~~

N-(1-aza-bicyclo[2.2.2]oct-3-yl)-2-(3,5-dichloro-phenylsulfanyl)-5-nitro-benzenesulfonamide; and

~~4-(3,5-dichlorophenoxy)-3-(4-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)piperidin-1-ylsulfonyl)benzonitrile;~~

~~(3'S,5'S)-methyl-1'-(5-cyano-2-(3,5-dichlorophenoxy)phenylsulfonyl)-1,3'-bipyrrolidine-5'-carboxylate;~~

~~3-(4-((3S,4S)-3-(tert-butyldimethylsilyloxy)-4-hydroxypyrrolidin-1-yl)piperidin-1-ylsulfonyl)-4-(3,5-dichlorophenoxy)benzonitrile;~~

~~4-(3,5-dichlorophenoxy)-3-((3S,3'S,4S)-3,4-dihydroxy-1,3'-bipyrrolidin-1'-ylsulfonyl)benzonitrile;~~

~~(S)-1-(1-(5-cyano-2-(3,5-dichlorophenoxy)phenylsulfonyl)piperidin-4-yl)pyrrolidine-2-carboxylic acid;~~

~~4-(3,5-dichlorophenoxy)-3-(2-((3-hydroxypyrrolidin-1-yl)methyl)piperidin-1-ylsulfonyl)benzonitrile; and~~

(R)-5-cyano-2-(3,5-dichlorophenoxy)-N-(2-(2,5-dioxopyrrolidin-1-yl)ethyl)-N-(1-aza-bicyclo[2.2.2]oct-3-yl)benzenesulfonamide.

6. (Previously Presented) A pharmaceutical composition comprising a compound of claim 1, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as an active ingredient.

7. (Previously Presented) The pharmaceutical composition of claim 6, further comprising one or more pharmaceutically acceptable excipients.

8. (Previously Presented) The pharmaceutical composition of claim 6, wherein said compound, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a CCR3 antagonist.

9. (Canceled).

10. (Previously Presented) The pharmaceutical composition of claim 9, wherein said inflammatory disorder or disease is selected from the group consisting of asthma, rhinitis, allergic diseases, and autoimmune pathologies.

11. (Currently Amended) The pharmaceutical composition of claim 6 suitable for the treatment ~~or prevention~~ of a disease selected from the group consisting of HIV infection, lung granuloma, and Alzheimer's diseases.

12. (Canceled).

13. (Currently Amended) A method of treating ~~The method of claim 12, wherein said disorder or disease is~~ an inflammatory or immunoregulatory disorder or disease comprising administering a compound of claim 1 or its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof.

14. (Currently Amended) The method of claim 13~~12~~, wherein said disorder or disease is selected from the group consisting of asthma, rhinitis, allergic diseases, and autoimmune pathologies.

15. (Currently Amended) The method of claim 13~~12~~, wherein said disorder or disease is selected from the group consisting of HIV infection, lung granuloma, and Alzheimer's diseases.

16. (Currently Amended) The method of claim 13~~12~~, wherein said compound~~benzenesulfonamide derivative~~, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is formulated with one or more pharmaceutically acceptable excipients.

17. – 19. (Canceled).

20. (Previously Presented) The pharmaceutical composition of claim 7, wherein the excipient is an inert substance such as a carrier, a diluent, a flavoring agent, a sweetener, a lubricant, a solubilizer, a suspending agent, a binder, a tablet disintegrating agent or an encapsuling agent.

21. (Previously Presented) The method of claim 16, wherein the excipient is an inert substance such as a carrier, a diluent, a flavoring agent, a sweetener, a lubricant, a solubilizer, a suspending agent, a binder, a tablet disintegrating agent or an encapsuling agent.